Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Participants receiving adjuvant nivolumab therapy could be enrolled prospectively and retrospectively.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection and have no evidence of disease.
Decision to treat with adjuvant nivolumab therapy has already been taken
At least 18 years of age at the time of treatment decision
Patients who provide written informed consent to participate in the study (for retrospectively enrolled patients who are deceased at time of study start, a consent waiver will be sought)
You may not be if
Any patient with a diagnosis of persisting advanced melanoma prior to first administration of nivolumab
Any patient currently enrolled in an interventional clinical trial for his/her melanoma treatment (note: patients who have completed their participation in an interventional trial or who are no longer receiving the study drug and are only followed up for Overall Survival (OS)/ Relapse Free Survival (RFS) can be enrolled. In case of a blinded study, the treatment arm needs to be known).
Clareo Health | A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
